Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹2205.57 Cr |
| Fresh Issue | ₹500.00 Cr |
| Offer for Sale | ₹1705.57 Cr |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹319.00-336.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543654 |
| NSE Code | MEDANTA |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Kotak Mahindra Capital Co.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 44 shares and in multiples thereof
Global Health Limited is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India. The company has key specialities in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.
Global Health Limited have a network of four hospitals currently in operation (Gurugram, Indore, Ranchi and Lucknow) under the "Medanta" brand. The company established "The Medanta Institutional Tissue Repository" in 2017 to promote biomarker and other tissue-based research.
In Fiscals 2020, 2021 and 2022 and the three months ended June 30, 2021 and 2022, the company generated income from healthcare services of Rs. 14,805.71 million, Rs. 14,178.41 million, Rs. 21,003.95 million, Rs. 4,732.10 million and Rs. 5,960.89 226 million, respectively, and had EBITDA of Rs. 2,304.54 million, Rs. 2,228.52 million, Rs. 4,897.57 million, Rs. 1,057.69 million and Rs. 1,416.46 million, respectively.
As of June 30, 2022, the company provide healthcare services in over 30 medical specialities and engage over 1,300 doctors led by experienced department heads, spanning an area of 4.7 million sq. ft., the operational hospitals have 2,467 installed beds.
Global Health Limited's hospital at Gurugram was ranked as the best private hospital in India for three consecutive years in 2020, 2021 and 2022, and was the only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 and was featured in the list of top 250 global hospitals in 2022 by Newsweek
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment/prepayment of borrowings, in full or part, of such Subsidiaries | 375.00 |
| 2 | General corporate purposes | 101.70 |
| Period Ended | 30 Jun 2022 | 31 Mar 2022 | 31 Mar 2021 | 30 Jun 2020 | 31 Mar 2020 |
|---|---|---|---|---|---|
| Assets | 3,221.94 | 3,145.52 | 2,694.11 | 2,855.11 | 2,666.29 |
| Total Income | 626.54 | 2,205.82 | 1,478.16 | 491.58 | 1,544.27 |
| Profit After Tax | 58.71 | 196.20 | 28.81 | 41.76 | 36.33 |
| NET Worth | 1,675.55 | 1,616.01 | 1,382.34 | 1,425.38 | 1,349.54 |
| Reserves and Surplus | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Borrowing | 794.45 | 837.86 | 644.60 | 725.07 | 621.94 |
| Amount in ₹ Crore | |||||
| KPI | |
|---|---|
| ROE | 13.1% |
| ROCE | 16.3% |
| Debt / Equity | 0.50% |
| RoNW | 12.14% |
| PAT Margin | 9.00% |
| EBITDA Margin | 21.92% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 7.78 | |
| P/E (x) | 38.36 | |
| Promoter Holding | 35% | 33% |
| Market Cap | ₹9011.01 Cr. | |
